Osigraft (eptotermin alfa)
- Region
- 🇪🇺 EU
- Active substance
- eptotermin alfa
- Company
- Olympus Biotech International Limited
- Status
- Withdrawn
- Therapeutic area
- Tibial Fractures
- EU approval
- Thu 17 May 2001
- Application
- EMEA/H/C/000293
- ATC
- M05BC02
- Official record
- www.ema.europa.eu
Indication
Treatment of nonunion of tibia of at least 9 month duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or use of autograft is unfeasible.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Opgenra Withdrawn · Olympus Biotech International Limited
Follow Osigraft
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.